Bicalutamide is an oral nonsteroidal antiandrogen medication used primarily in the treatment of prostate cancer. It works by binding to androgen receptors and blocking the interaction of testosterone with these receptors. This competitive antagonism prevents the activation of genes that are driven by androgen signaling. The blockade of androgen activity leads to reduced proliferation of prostate cancer cells and slower disease progression. Clinically the drug is administered as a daily tablet and is often combined with other therapies such as luteinizing hormone-releasing hormone analogs. The primary therapeutic role of Bicalutamide is to reduce testosterone-mediated stimulation of malignant prostate tissue thereby improving survival outcomes. Pharmacodynamically the drug selectively occupies androgen receptors in target cells while showing minimal partial agonist activity which limits hormonal flare effects. Through its antagonistic mechanism the medication achieves sustained suppression of androgen-driven proliferation without significant systemic estrogenic or glucocorticoid activity.

Bicalutamide is an oral nonsteroidal antiandrogen that blocks androgen receptors in target tissues. It is used primarily in the treatment of advanced prostate cancer to inhibit the effects of testosterone. By competitively binding to the androgen receptor it prevents the activation of genes that promote tumor growth. The drug reduces circulating androgen activity without altering its synthesis leading to decreased cellular proliferation. Lack of steroidal structure allows it to maintain receptor affinity while avoiding metabolic activation typical of steroidal agents. This mechanism provides sustained suppression of androgen driven disease progression.

Bicalutamide may cause hot flashes and mild skin irritation in some patients. It can affect liver function tests and rarely leads to elevated enzyme levels. Some users experience decreased sexual desire or erectile dysfunction as hormonal shifts occur. Breast tenderness or enlargement has been reported in a small percentage of cases. The medication may cause mild nausea or fatigue during the early weeks of treatment. Hair loss is uncommon but has been documented in isolated reports.

Bicalutamide is an oral medication primarily used in the treatment of prostate cancer. Common side effects include hot flashes and excessive sweating that may affect daily comfort. Some patients experience breast tenderness or enlargement due to hormonal changes. Liver function abnormalities such as elevated enzymes can occur and require periodic monitoring. Sexual function may be impacted with decreased libido or difficulty achieving erection. Gastrointestinal symptoms like nausea or loss of appetite are also reported in a minority of cases. Rare but serious reactions such as allergic skin rash or severe liver injury have been documented in isolated cases.